(1) Background: There is a huge unmet clinical need for novel treatment strategies in advanced and recurrent cervical cancer. Several cell membrane-bound molecules are up-regulated in cancer cells as compared to normal tissue and have revived interest with the introduction of antibody–drug conjugates (ADCs). (2) Methods: In this study, we characterize the expression of 10 potential ADC targets, TROP2, mesotheline, CEACAM5, DLL3, folate receptor alpha, guanylatcyclase, glycoprotein NMB, CD56, CD70 and CD138, on the gene expression level. Of these, the three ADC targets TROP2, CEACAM5 and CD138 were further analyzed on the protein level. (3) Results: TROP2 shows expression in 98.5% (66/67) of cervical cancer samples. CEACAM5 shows a stable gene expression profile and overall, 68.7% (46/67) of cervical cancer samples are CEACAM-positive with 34.3% (23/67) of cervical cancer samples showing at least moderate or high expression. Overall, 73.1% (49/67) of cervical cancer samples are CD138-positive with 38.8% (26/67) of cervical cancer samples showing at least moderate or high expression. (4) Conclusions: TROP2, CEACAM5 or CD138 do seem suitable for further clinical research and the data presented here might be used to guide further clinical trials with ADCs in advanced and recurrent cervical cancer patients.
(1) 背景：晚期及复发性宫颈癌的治疗策略存在巨大的未满足临床需求。相较于正常组织，癌细胞中多种细胞膜结合分子表达上调，随着抗体偶联药物（ADCs）的引入，这些分子重新引起研究关注。(2) 方法：本研究在基因表达水平上分析了10种潜在ADC靶点的表达特征，包括TROP2、间皮素、CEACAM5、DLL3、叶酸受体α、鸟苷酸环化酶、糖蛋白NMB、CD56、CD70和CD138。其中对TROP2、CEACAM5和CD138三种ADC靶点进一步进行了蛋白水平分析。(3) 结果：TROP2在98.5%（66/67）的宫颈癌样本中表达；CEACAM5呈现稳定的基因表达谱，总体68.7%（46/67）的宫颈癌样本呈CEACAM5阳性，其中34.3%（23/67）的样本显示至少中度或高度表达；总体73.1%（49/67）的宫颈癌样本呈CD138阳性，其中38.8%（26/67）的样本显示至少中度或高度表达。(4) 结论：TROP2、CEACAM5和CD138均适合开展进一步临床研究，本研究数据可为晚期及复发性宫颈癌患者的ADC临床试验提供指导依据。
Expression of Potential Antibody–Drug Conjugate Targets in Cervical Cancer
肿瘤(癌症)患者之家